|
1
|
Nasri H and Rafieian-Kopaei M: Metformin:
Current knowledge. J Res Med Sci. 19:658–664. 2014.
|
|
2
|
Top WMC, Kooy A and Stehouwer CDA:
Metformin: A narrative review of its potential benefits for
cardiovascular disease, cancer and dementia. Pharmaceuticals
(Basel). 15:3122022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kramer JR, Natarajan Y, Dai J, Yu X, Li L,
El-Serag HB and Kanwal F: Effect of diabetes medications and
glycemic control on risk of hepatocellular cancer in patients with
nonalcoholic fatty liver disease. Hepatology. 15:322442021.
View Article : Google Scholar
|
|
4
|
Gralewska P, Gajek A, Marczak A and
Rogalska A: Metformin affects olaparib sensitivity through
induction of apoptosis in epithelial ovarian cancer cell lines. Int
J Mol Sci. 22:105572021. View Article : Google Scholar
|
|
5
|
Tsogas FK, Majerczyk D and Hart PC:
Possible role of metformin as an immune modulator in the tumor
microenvironment of ovarian cancer. Int J Mol Sci. 22:8672021.
View Article : Google Scholar
|
|
6
|
Adeyemi SA and Choonara YE: Current
advances in cell therapeutics: A biomacromolecules application
perspective. Expert Opin Drug Deliv. 12:1–18. 2022. View Article : Google Scholar
|
|
7
|
Liao M, Qin R, Huang W, Zhu HP, Peng F,
Han B and Liu B: Targeting regulated cell death (RCD) with
small-molecule compounds in triple-negative breast cancer: A
revisited perspective from molecular mechanisms to targeted
therapies. J Hematol Oncol. 15:442022. View Article : Google Scholar
|
|
8
|
Marciano O, Mehazri L, Shpungin S, Varvak
A, Zacksenhaus E and Nir U: Fer and fert govern mitochondrial
susceptibility to metformin and hypoxic stress in colon and lung
carcinoma cells. Cells. 10:972021. View Article : Google Scholar
|
|
9
|
Mohammadi S, Arefnezhad R, Danaii S and
Yousefi M: New insights into the core Hippo signaling and
biological macromolecules interactions in the biology of solid
tumors. Biofactors. 46:514–530. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim YS, Hwang KA, Go RE, Kim CW and Choi
KC: Gene therapy strategies using engineered stem cells for
treating gynecologic and breast cancer patients (Review). Oncol
Rep. 33:2107–2112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hotta K, Kiura K, Ueoka H, Tabata M,
Fujiwara K, Kozuki T, Okada T, Hisamoto A and Tanimoto M: Effect of
gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with
advanced non-small-cell lung cancer. Lung Cancer. 46:255–261. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lankheet NA, Schaake EE, Burgers SA, van
Pel R, Beijnen JH, Huitema ADR and Klomp H; NEL Study Group, :
Concentrations of erlotinib in tumor tissue and plasma in
non-small-cell lung cancer patients after neoadjuvant therapy. Clin
Lung Cancer. 16:320–324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zitvogel L, Rusakiewicz S, Routy B, Ayyoub
M and Kroemer G: Immunological off-target effects of imatinib. Nat
Rev Clin Oncol. 13:431–446. 2016. View Article : Google Scholar
|
|
14
|
Joensuu H: Treatment of inoperable
gastrointestinal stromal tumor (GIST) with imatinib (Glivec,
Gleevec). Med Klin (Munich). 15 (Suppl 1):S28–S30. 2002.
|
|
15
|
Cohen C, Pop D, Icard P, Berthet JP,
Venissac N and Mouroux J: Is there a place for thoracoscopic
enucleation of esophageal gastrointestinal stromal tumors? Thorac
Cardiovasc Surg. 67:585–588. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen YH, Yang SF, Yang CK, Tsai HD, Chen
TH, Chou MC and Hsiao YH: Metformin induces apoptosis and inhibits
migration by activating the AMPK/p53 axis and suppressing PI3K/AKT
signaling in human cervical cancer cells. Mol Med Rep. 23:882021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng L, Lv W, Zhou Y, Lin X and Yao J:
Progress on the mechanism for aspirin's anti-tumor effects. Curr
Drug Targets. 22:105–111. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pereira PMR, Mandleywala K, Ragupathi A
and Lewis JS: Acute statin treatment improves antibody accumulation
in EGFR- and PSMA-expressing tumors. Clin Cancer Res. 26:6215–6229.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pereira A, de Souza Lima ML, da
Silva-Junior AA, Silva EDS, de Araújo Júnior RF, Martins AA, Alves
JSF, de Santana Oliveira A, Ferreira LDS, de Araújo Costa ECT, et
al: In vitro-in vivo availability of metformin hydrochloride-PLGA
nanoparticles in diabetic rats in a periodontal disease
experimental model. Pharm Biol. 59:1576–1584. 2021. View Article : Google Scholar
|
|
20
|
Horas K, van Herck U, Maier GS, Maus U,
Harrasser N, Jakob F, Weissenberger M, Arnholdt J, Holzapfel BM and
Rudert M: Does vitamin D deficiency predict tumour malignancy in
patients with bone tumours? Data from a multi-center cohort
analysis. J Bone Oncol. 25:1003292020. View Article : Google Scholar
|
|
21
|
Zeng L, Holly JM and Perks CM: Effects of
physiological levels of the green tea extract
epigallocatechin-3-gallate on breast cancer cells. Front Endocrinol
(Lausanne). 5:612014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Varghese S, Samuel SM, Varghese E, Kubatka
P and Büsselberg D: High glucose represses the anti-proliferative
and pro-apoptotic effect of metformin in triple negative breast
cancer cells. Biomolecules. 9:162019. View Article : Google Scholar
|
|
23
|
Kawakita E, Yang F, Kumagai A, Takagaki Y,
Kitada M, Yoshitomi Y, Ikeda T, Nakamura Y, Ishigaki Y, Kanasaki K
and Koya D: Metformin mitigates DPP-4 inhibitor-induced breast
cancer metastasis via suppression of mTOR signaling. Mol Cancer
Res. 19:61–73. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stage TB, Brøsen K and Christensen MM: A
comprehensive review of drug-drug interactions with metformin. Clin
Pharmacokinet. 54:811–824. 2015. View Article : Google Scholar
|
|
25
|
Bian X, Jiang L, Gan Z, Zhang L, Cai L and
Hu X: A glimepiride-metformin multidrug crystal: Synthesis, crystal
structure analysis, and physicochemical properties. Molecules.
24:37862019. View Article : Google Scholar
|
|
26
|
Scheen AJ: Clinical pharmacokinetics of
metformin. Clin Pharmacokinet. 30:359–371. 1996. View Article : Google Scholar
|
|
27
|
Palumbo PJ: Metformin: Effects on
cardiovascular risk factors in patients with non-insulin-dependent
diabetes mellitus. J Diabetes Complications. 12:110–119. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mbara KC, Mato PE, Driver C, Nzuza S,
Mkhombo NT, Gcwensa SK, Mcobothi EN and Owira PM: Metformin turns
62 in pharmacotherapy: Emergence of non-glycaemic effects and
potential novel therapeutic applications. Eur J Pharmacol.
898:1739342021. View Article : Google Scholar
|
|
29
|
Notaro ALG and Neto FTL: The use of
metformin in women with polycystic ovary syndrome: An updated
review. J Assist Reprod Genet. 14:573–579. 2022. View Article : Google Scholar
|
|
30
|
Yu Y, Yu L, Cheng N, Liu X, Fang C, Liu S
and Zhu L: Exercise alleviates the apolipoprotein A5-toll-like
receptor 4 axis impairment in mice with high-fat diet-induced
non-alcoholic steatohepatitis. Front Physiol. 12:7833412021.
View Article : Google Scholar
|
|
31
|
Kalariya NM, Shoeb M, Ansari NH,
Srivastava SK and Ramana KV: Antidiabetic drug metformin suppresses
endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci.
53:3431–3440. 2012. View Article : Google Scholar
|
|
32
|
Agostini F, Masato A, Bubacco L and
Bisaglia M: Metformin repurposing for parkinson disease therapy:
Opportunities and challenges. Int J Mol Sci. 23:3982021. View Article : Google Scholar
|
|
33
|
Ma X, Xiao W, Li H, Pang P, Xue F, Wan L,
Pei L and Yan H: Metformin restores hippocampal neurogenesis and
learning and memory via regulating gut microbiota in the obese
mouse model. Brain Behav Immun. 95:68–83. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim JW, Choe JY and Park SH: Metformin and
its therapeutic applications in autoimmune inflammatory rheumatic
disease. Korean J Intern Med. 37:13–26. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Siskind D, Friend N, Russell A, McGrath
JJ, Lim C, Patterson S, Flaws D, Stedman T, Moudgil V and Sardinha
S: CoMET: A protocol for a randomised controlled trial of
co-commencement of METformin as an adjunctive treatment to
attenuate weight gain and metabolic syndrome in patients with
schizophrenia newly commenced on clozapine. BMJ Open.
8:e0210002018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Taylor A, Siddiqui MK, Ambery P, Armisen
J, Challis BG, Haefliger C, Pearson ER, Doney ASF, Dillon JF and
Palmer CNA: Metabolic dysfunction-related liver disease as a risk
factor for cancer. BMJ Open Gastroenterol. 9:e0008172022.
View Article : Google Scholar
|
|
37
|
Sousa AP, Costa R, Alves MG, Soares R,
Baylina P and Fernandes R: The impact of metabolic syndrome and
type 2 diabetes mellitus on prostate cancer. Front Cell Dev Biol.
10:8434582022. View Article : Google Scholar
|
|
38
|
Yang J, Nishihara R, Zhang X, Ogino S and
Qian ZR: Energy sensing pathways: Bridging type 2 diabetes and
colorectal cancer? J Diabetes Complications. 31:1228–1236. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kabat GC, Kim M, Chlebowski RT, Khandekar
J, Ko MG, McTiernan A, Neuhouser ML, Parker DR, Shikany JM,
Stefanick ML, et al: A longitudinal study of the metabolic syndrome
and risk of postmenopausal breast cancer. Cancer Epidemiol
Biomarkers Prev. 18:2046–2053. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang X and Ding S: The biological and
pharmacological connections between diabetes and various types of
cancer. Pathol Res Pract. 227:1536412021. View Article : Google Scholar
|
|
41
|
Cook A and Cowan C: Adipose. StemBook.
Harvard Stem Cell Institute; Cambridge, MA: 2008
|
|
42
|
Menendez JA, Vazquez-Martin A, Ortega FJ
and Fernandez-Real JM: Fatty acid synthase: Association with
insulin resistance, type 2 diabetes, and cancer. Clin Chem.
55:425–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
LeRoith D, Novosyadlyy R, Gallagher EJ,
Lann D, Vijayakumar A and Yakar S: Obesity and type 2 diabetes are
associated with an increased risk of developing cancer and a worse
prognosis; epidemiological and mechanistic evidence. Exp Clin
Endocrinol Diabetes. 116 (Suppl 1):S4–S6. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jayalath VH, Ireland C, Fleshner NE,
Hamilton RJ and Jenkins DJ: The relationship between metformin and
serum prostate-specific antigen levels. Prostate. 76:1445–1453.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park JH, Hong JY, Park YS, Kang G, Han K
and Park JO: Association of prediabetes, diabetes, and diabetes
duration with biliary tract cancer risk: A nationwide cohort study.
Metabolism. 123:1548482021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang AMY, Chu KH, Daly BF, Ruiter T, Dou
Y, Yang JCC, de Winter TJJ, Chhuor J, Wang S, Flibotte S, et al:
Effects of hyperinsulinemia on pancreatic cancer development and
the immune microenvironment revealed through single-cell
transcriptomics. Cancer Metab. 10:52022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lu L, Koo S, McPherson S, Hull MA, Rees CJ
and Sharp L: Systematic review and meta-analysis: Associations
between metabolic syndrome and colorectal neoplasia outcomes.
Colorectal Dis. 13:160922022. View Article : Google Scholar
|
|
48
|
Nayak S, Rathore V, Bharati J and Sahu KK:
Extending the ambit of SGLT2 inhibitors beyond diabetes: A review
of clinical and preclinical studies on non-diabetic kidney disease.
Expert Rev Clin Pharmacol. 14:1513–1526. 2021. View Article : Google Scholar
|
|
49
|
Lam BQ, Srivastava R, Morvant J, Shankar S
and Srivastava RK: Association of diabetes mellitus and alcohol
abuse with cancer: Molecular mechanisms and clinical significance.
Cells. 10:30772021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Srinivasan M, Arzoun H, Gk LB and
Thangaraj SR: A systematic review: Does insulin resistance affect
the risk and survival outcome of breast cancer in women? Cureus.
14:e217122022.PubMed/NCBI
|
|
51
|
Lemon LS, Orr B, Modugno F, Buckanovich
RJ, Coffman L, Edwards RP and Taylor S: Metformin and survival: Is
there benefit in a cohort limited to diabetic women with
endometrial, breast, or ovarian cancer? Gynecol Oncol. 165:60–66.
2022. View Article : Google Scholar
|
|
52
|
Choi E, Kikuchi S, Gao H, Brodzik K,
Nassour I, Yopp A, Singal AG, Zhu H and Yu H: Mitotic regulators
and the SHP2-MAPK pathway promote IR endocytosis and feedback
regulation of insulin signaling. Nat Commun. 10:14732019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang L, Zhang B, Zheng W, Kang M, Chen Q,
Qin W, Li C, Zhang Y, Shao Y and Wu Y: Exosomes derived from
pancreatic cancer cells induce insulin resistance in C2C12 myotube
cells through the PI3K/Akt/FoxO1 pathway. Sci Rep. 7:53842017.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yang X, Huang M, Zhang Q, Chen J, Li J,
Han Q, Zhang L, Li J, Liu S, Ma Y, et al: Metformin antagonizes
ovarian cancer cells malignancy through MSLN mediated IL-6/STAT3
signaling. Cell Transplant. 30:96368972110278192021. View Article : Google Scholar
|
|
55
|
Rho SB, Byun HJ, Kim BR and Lee CH:
Knockdown of LKB1 sensitizes endometrial cancer cells via AMPK
activation. Biomol Ther. 29:650–657. 2021. View Article : Google Scholar
|
|
56
|
Cheng T, Wang C, Lu Q, Cao Y, Yu W, Li W,
Liu B, Gao X, Lü J and Pan X: Metformin inhibits the
tumor-promoting effect of low-dose resveratrol, and enhances the
anti-tumor activity of high-dose resveratrol by increasing its
reducibility in triple negative breast cancer. Free Radic Biol Med.
180:108–120. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Eze C, Belka C and Manapov F: Forging a
path for metformin use in inoperable locally advanced non-small
cell lung cancer. JAMA Oncol. 7:1341–1342. 2021. View Article : Google Scholar
|
|
58
|
Mazurek M, Litak J, Kamieniak P, Kulesza
B, Jonak K, Baj J and Grochowski C: Metformin as potential therapy
for high-grade glioma. Cancers (Basel). 12:2102020. View Article : Google Scholar
|
|
59
|
Zhao A, Xiao H, Zhu Y, Liu S, Zhang S,
Yang Z, Du L, Li X, Niu X, Wang C, et al: Omentin-1: A newly
discovered warrior against metabolic related diseases. Expert Opin
Ther Targets. 10:275–289. 2022. View Article : Google Scholar
|
|
60
|
Eibl G and Rozengurt E: Metformin: Review
of epidemiology and mechanisms of action in pancreatic cancer.
Cancer Metastasis Rev. 40:865–878. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang CP, Kuhn J, Shah DP, Schmidt S, Lam
YWF, MacCarthy D, Tenner L and Ramirez AG: Metformin modifies
disparity in hepatocellular carcinoma incidence in men with type 2
diabetes but without chronic liver diseases. Cancer Med.
8:3206–3215. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Erkinantti S, Marttila M, Sund R, Arffman
M, Urpilainen E, Puistola U, Hautakoski A, Karihtala P, Läärä E and
Jukkola A: Association of metformin, other antidiabetic
medications, and statins with incidence of colon cancer in patients
with type 2 diabetes. Clin Colorectal Cancer. 20:e113–e119. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Febbraro T, Lengyel E and Romero IL: Old
drug, new trick: Repurposing metformin for gynecologic cancers?
Gynecol Oncol. 135:614–621. 2014. View Article : Google Scholar
|
|
64
|
Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D,
Xie J, Tao M and Mao Y: Metformin use is associated with better
survival of breast cancer patients with diabetes: A meta-analysis.
Oncologist. 20:1236–1244. 2015. View Article : Google Scholar
|
|
65
|
Wang Q, Ma X, Long J, Du X, Pan B and Mao
H: Metformin and survival of women with breast cancer: A
meta-analysis of randomized controlled trials. J Clin Pharm Ther.
16:135002021.
|
|
66
|
Tseng CH: Metformin significantly reduces
incident prostate cancer risk in Taiwanese men with type 2 diabetes
mellitus. Eur J Cancer. 50:2831–2837. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Brancher S, Støer NC, Weiderpass E,
Damhuis RAM, Johannesen TB, Botteri E and Strand TE: Metformin use
and lung cancer survival: A population-based study in Norway. Br J
Cancer. 124:1018–1025. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tseng CH: Metformin reduces thyroid cancer
risk in taiwanese patients with type 2 diabetes. PLoS One.
9:e1098522014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Agrawal S, Patel P, Agrawal A, Makhijani
N, Markert R and Deidrich W: Metformin use and the risk of
esophageal cancer in Barrett esophagus. South Med J. 107:774–779.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Becker C, Jick SS, Meier CR and Bodmer M:
Metformin and the risk of endometrial cancer: A case-control
analysis. Gynecol Oncol. 129:565–569. 2013. View Article : Google Scholar
|
|
71
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care.
29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Gandini S, Puntoni M, Heckman-Stoddard BM,
Dunn BK, Ford L, DeCensi A and Szabo E: Metformin and cancer risk
and mortality: A systematic review and meta-analysis taking into
account biases and confounders. Cancer Prev Res (Phila). 7:867–885.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wu Z, Wu L, Zou L, Wang M and Liu X:
Metformin induces myeloma cells necrosis and apoptosis and it is
considered for therapeutic use. J Chemother. 15:1–11. 2022.
View Article : Google Scholar
|
|
74
|
Teixeira SF, Guimarães IDS, Madeira KP,
Daltoé RD, Silva IV and Rangel LB: Metformin synergistically
enhances antiproliferative effects of cisplatin and etoposide in
NCI-H460 human lung cancer cells. J Bras Pneumol. 39:644–649.
2013.(In English, Portuguese). View Article : Google Scholar
|
|
75
|
Lin F, Yan W, Wen T and Wu GY: Metformin
induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro
and its mechanism. Zhonghua Zhong Liu Za Zhi. 35:742–746. 2013.(In
Chinese).
|
|
76
|
Huang X, Hong X, Wang J, Sun T, Yu T, Yu
Y, Fang J and Xiong H: Metformin elicits antitumour effect by
modulation of the gut microbiota and rescues Fusobacterium
nucleatum-induced colorectal tumourigenesis. EBioMedicine.
61:1030372020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Phoenix KN, Vumbaca F and Claffey KP:
Therapeutic metformin/AMPK activation promotes the angiogenic
phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
Breast Cancer Res Treat. 113:101–111. 2009. View Article : Google Scholar
|
|
78
|
Anisimov VN, Egormin PA, Piskunova TS,
Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV,
Karkach AS and Romanyukha AA: Metformin extends life span of
HER-2/neu transgenic mice and in combination with melatonin
inhibits growth of transplantable tumors in vivo. Cell Cycle.
9:188–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Memmott RM, Mercado JR, Maier CR, Kawabata
S, Fox SD and Dennis PA: Metformin prevents tobacco
carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila).
3:1066–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zhang S, Lachance BB, Mattson MP and Jia
X: Glucose metabolic crosstalk and regulation in brain function and
diseases. Prog Neurobiol. 204:1020892021. View Article : Google Scholar
|
|
81
|
Dai JZ, Wang YJ, Chen CH, Tsai IL, Chao YC
and Lin CW: YAP dictates mitochondrial redox homeostasis to
facilitate obesity-associated breast cancer progression. Adv Sci.
18:e21036872022. View Article : Google Scholar
|
|
82
|
Fleming JB, Gonzalez RJ, Petzel MQ, Lin E,
Morris JS, Gomez H, Lee JE, Crane CH, Pisters PWT and Evans DB:
Influence of obesity on cancer-related outcomes after
pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg.
144:216–221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Purcell SA, Oliveira CLP, Mackenzie M,
Robson P, Lewis J and Prado CM: Body composition and prostate
cancer risk: A systematic review of observational studies. Adv
Nutr. 16:1532021. View Article : Google Scholar
|
|
84
|
Gong L, Wang Z and Zhang Z: Sestrin2 as a
potential target for regulating metabolic-related diseases. Front
Endocrinol (Lausanne). 12:7510202021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zell JA, McLaren CE, Morgan TR, Lawson MJ,
Rezk S, Albers CG, Chen WP, Carmichael JC, Chung J, Richmond E, et
al: A phase IIa trial of metformin for colorectal cancer risk
reduction among individuals with history of colorectal adenomas and
elevated body mass index. Cancer Prev Res (Phila). 13:203–212.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Saini N and Yang X: Metformin as an
anti-cancer agent: Actions and mechanisms targeting cancer stem
cells. Acta Biochim Biophys Sin (Shanghai). 50:133–143. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Bang S, Chen Y, Ahima RS and Kim SF:
Convergence of IPMK and LKB1-AMPK signaling pathways on metformin
action. Mol Endocrinol. 28:1186–1193. 2014. View Article : Google Scholar
|
|
88
|
Najafov A, Luu HS, Mookhtiar AK, Mifflin
L, Xia HG, Amin PP, Ordureau A, Wang H and Yuan J: RIPK1 promotes
energy sensing by the mTORC1 pathway. Mol Cell. 81:370–385. 2021.
View Article : Google Scholar
|
|
89
|
Kim BH, Han S, Lee H, Park CH, Chung YM,
Shin K, Lee HG and Ye SK: Metformin enhances the anti-adipogenic
effects of atorvastatin via modulation of STAT3 and TGF-β/Smad3
signaling. Biochem Biophys Res Commun. 456:173–178. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Xu S, Lam SK, Cheng PN and Ho JC:
Recombinant human arginase induces apoptosis through oxidative
stress and cell cycle arrest in small cell lung cancer. Cancer Sci.
109:3471–3482. 2018. View Article : Google Scholar
|
|
91
|
Cameron AR, Logie L, Patel K, Erhardt S,
Bacon S, Middleton P, Harthill J, Forteath C, Coats JT, Kerr C, et
al: Metformin selectively targets redox control of complex I energy
transduction. Redox Biol. 14:187–197. 2018. View Article : Google Scholar
|
|
92
|
Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin
W, Ke J, Huang J, Yeung SCJ and Zhang H: Metformin promotes
autophagy and apoptosis in esophageal squamous cell carcinoma by
downregulating Stat3 signaling. Cell Death Dis. 5:e10882014.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Janjetovic K, Vucicevic L, Misirkic M,
Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S,
Bumbasirevic V, Trajkovic V and Harhaji-Trajkovic L: Metformin
reduces cisplatin-mediated apoptotic death of cancer cells through
AMPK-independent activation of Akt. Eur J Pharmacol. 651:41–50.
2011. View Article : Google Scholar
|
|
94
|
Athreya AP, Kalari KR, Cairns J, Gaglio
AJ, Wills QF, Niu N, Weinshilboum R, Iyer RK and Wang L:
Model-based unsupervised learning informs metformin-induced
cell-migration inhibition through an AMPK-independent mechanism in
breast cancer. Oncotarget. 8:27199–27215. 2017. View Article : Google Scholar
|
|
95
|
Yenmiş G, Beşli N, Saraç EY, Emre FS,
Şenol K and Kanıgür G: Metformin promotes apoptosis in primary
breast cancer cells by downregulation of cyclin D1 and upregulation
of P53 through an AMPK-alpha independent mechanism. Turk J Med Sci.
51:826–834. 2021. View Article : Google Scholar
|
|
96
|
Calza G, Nyberg E, Mäkinen M, Soliymani R,
Cascone A, Lindholm D, Barborini E, Baumann M, Lalowski M and
Eriksson O: Lactate-induced glucose output is unchanged by
metformin at a therapeutic concentration-a mass spectrometry
imaging study of the perfused rat liver. Front Pharmacol.
9:1412018. View Article : Google Scholar
|
|
97
|
Thakur S, Daley B, Gaskins K, Vasko VV,
Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, et
al: Metformin targets mitochondrial glycerophosphate dehydrogenase
to control rate of oxidative phosphorylation and growth of thyroid
cancer in vitro and in vivo. Clin Cancer Res. 24:4030–4043. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Salani B, Marini C, Rio AD, Ravera S,
Massollo M, Orengo AM, Amaro A, Passalacqua M, Maffioli S, Pfeffer
U, et al: Metformin impairs glucose consumption and survival in
Calu-1 cells by direct inhibition of hexokinase-II. Sci Rep.
3:20702013. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Jiang Y, Xu D, Song H, Qiu B, Tian D, Li
Z, Ji Y and Wang J: Inflammation and nutrition-based biomarkers in
the prognosis of oesophageal cancer: A systematic review and
meta-analysis. BMJ Open. 11:e0483242021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
El-Tanani M, Al Khatib AO, Aladwan SM,
Abuelhana A, McCarron PA and Tambuwala MM: Importance of STAT3
signalling in cancer, metastasis and therapeutic interventions.
Cell Signal. 92:1102752022. View Article : Google Scholar
|
|
101
|
Zahra MH, Afify SM, Hassan G, Nawara HM,
Kumon K, Seno A and Seno M: Metformin suppresses self-renewal and
stemness of cancer stem cell models derived from pluripotent stem
cells. Cell Biochem Funct. 39:896–907. 2021. View Article : Google Scholar
|
|
102
|
Higurashi T, Hosono K, Takahashi H, Komiya
Y, Umezawa S, Sakai E, Uchiyama T, Taniguchi L, Hata Y, Uchiyama S,
et al: Metformin for chemoprevention of metachronous colorectal
adenoma or polyps in post-polypectomy patients without diabetes: A
multicentre double-blind, placebo-controlled, randomised phase 3
trial. Lancet Oncol. 17:475–483. 2016. View Article : Google Scholar
|
|
103
|
Arrieta O, Zatarain-Barrón ZL, Turcott JG,
Barrón F, Yendamuri S, Cardona AF and Rosell R: Association of BMI
with benefit of metformin plus epidermal growth factor
receptor-tyrosine kinase inhibitors in patients with advanced lung
adenocarcinoma: A secondary analysis of a phase 2 randomized
clinical trial. JAMA Oncol. 8:477–479. 2022. View Article : Google Scholar
|
|
104
|
Pusceddu S, Vernieri C, Di Maio M, Prinzi
N, Torchio M, Corti F, Coppa J, Buzzoni R, Bartolomeo MD, Milione
M, et al: Impact of diabetes and metformin use on enteropancreatic
neuroendocrine tumors: Post hoc analysis of the CLARINET study.
Cancers (Basel). 14:692021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wang S, Lin Y, Xiong X, Wang L, Guo Y,
Chen Y, Chen S, Wang G, Lin P, Chen H, et al: Low-dose metformin
reprograms the tumor immune microenvironment in human esophageal
cancer: Results of a phase II clinical trial. Clin Cancer Res.
26:4921–4932. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Maruthur NM, Tseng E, Hutfless S, Wilson
LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB and Bolen
S: Diabetes medications as monotherapy or metformin-based
combination therapy for type 2 diabetes: A systematic review and
meta-analysis. Ann Intern Med. 164:740–751. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wink KC, Belderbos JS, Dieleman EM, Rossi
M, Rasch CRN, Damhuis RAM, Houben RMA and Troost EGC: Improved
progression free survival for patients with diabetes and locally
advanced non-small cell lung cancer (NSCLC) using metformin during
concurrent chemoradiotherapy. Radiother Oncol. 118:453–459. 2016.
View Article : Google Scholar
|
|
108
|
Martin MJ, Hayward R, Viros A and Marais
R: Metformin accelerates the growth of BRAF V600E-driven melanoma
by upregulating VEGF-A. Cancer Discov. 2:344–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
